Optimal cell concentration for cryopreservation of banked human adipose tissue-derived stem cells.
Li Z., Liu C., Mu D., Fu S., Li S., Wang Q.
Laboratory Study, published in Cytotechnology (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cytotechnology (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41409878
- DOI
- 10.1007/s10616-025-00877-6
Abstract (original English)
Human adipose tissue-derived stem cells (hADSCs) are an attractive source for regenerative medicine. However, cryopreservation protocols-particularly with respect to optimal cell concentration-remain inadequately defined. hADSCs were isolated from adipose tissue of 12 donors (mean age: 31.8 ± 8.9 years; BMI: 22.9 ± 4.2). Second-passage cells were cryopreserved for two weeks at concentrations of 0.5 × 10⁶/mL, 1 × 10⁶/mL, 2 × 10⁶/mL, 5 × 10⁶/mL, and 10 × 10⁶/mL. Post-thaw viability, apoptosis, immunophenotype, proliferation, and tri-lineage differentiation were evaluated using standard assays. Cell viability increased significantly with higher cryopreservation concentrations, reaching 94.2 ± 2.0% at 10 × 10⁶/mL ( p < 0.05 vs. 0.5 × 10⁶/mL). Early apoptosis decreased with increasing concentration, reaching its lowest level at 5 × 10⁶/mL (2.9 ± 0.5%; p < 0.05 vs. 10 × 10⁶/mL), but showed a slight increase at 10 × 10⁶/mL. Proliferation and tri-lineage differentiation into adipocytes, osteoblasts, and chondrocytes were maintained across all groups, as confirmed by histological staining and molecular analyses. Cryopreservation at 5 × 10⁶/mL offers the most favorable balance between high viability and minimal apoptosis while preserving proliferative and differentiation potential. This concentration likely represents an optimal condition for hADSC biobanking and clinical use. The online
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.